Ulrich Steidl

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6921109/publications.pdf

Version: 2024-02-01

114 papers	5,255 citations	76326 40 h-index	91884 69 g-index
116 all docs	116 docs citations	116 times ranked	8838 citing authors

#	Article	IF	Citations
1	The DNA dioxygenase Tet1 regulates H3K27 modification and embryonic stem cell biology independent of its catalytic activity. Nucleic Acids Research, 2022, 50, 3169-3189.	14.5	27
2	Posttranscriptional Arid3a deregulation in AMKL. Blood, 2022, 139, 637-638.	1.4	0
3	High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. Nature Medicine, 2022, 28, 468-471.	30.7	19
4	Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer. Journal of Hematology and Oncology, 2022, 15, .	17.0	6
5	Preleukemic and leukemic evolution at the stem cell level. Blood, 2021, 137, 1013-1018.	1.4	9
6	Stem cell origins of JMML. Journal of Experimental Medicine, 2021, 218, .	8.5	2
7	Epigenetic modifiers in normal and aberrent erythropoeisis. Seminars in Hematology, 2021, 58, 15-26.	3.4	1
8	An Evolutionary Approach to Clonally Complex Hematologic Disorders. Blood Cancer Discovery, 2021, 2, 201-215.	5.0	6
9	MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell, 2021, 39, 529-547.e7.	16.8	17
10	Epigenetic Achillesâ€™ heel of AML. Nature Cancer, 2021, 2, 481-483.	13.2	0
11	Gene expression at a single-molecule level: implications for myelodysplastic syndromes and acute myeloid leukemia. Blood, 2021, 138, 625-636.	1.4	3
12	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clinical Cancer Research, 2021, 27, 5236-5247.	7.0	74
13	Transcriptional control of CBX5 by the RNA-binding proteins RBMX and RBMXL1 maintains chromatin state in myeloid leukemia. Nature Cancer, 2021, 2, 741-757.	13.2	10
14	ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood Cancer Journal, 2021, 11, 157.	6.2	27
15	Exploiting a key transcriptional dependency: ZMYND8 and IRF8 in AML. Molecular Cell, 2021, 81, 3445-3446.	9.7	1
16	Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML. Experimental Hematology and Oncology, 2021, 10, 1.	5.0	17
17	Transcriptional circuit dynamics in HSPCs. Blood, 2021, 138, 1382-1384.	1.4	0
18	Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML). Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036251.	6.2	17

#	Article	IF	Citations
19	Single-molecule imaging of transcription dynamics in somatic stem cells. Nature, 2020, 583, 431-436.	27.8	61
20	H1 linker histones silence repetitive elements by promoting both histone H3K9 methylation and chromatin compaction. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 14251-14258.	7.1	57
21	A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy. Nature Cancer, 2020, 1, 315-328.	13.2	78
22	Fueling clonal dominance through TRAFficking of NF-Î¹B signaling. Nature Immunology, 2020, 21, 489-490.	14.5	2
23	Runx1 promotes murine erythroid progenitor proliferation and inhibits differentiation by preventing Pu.1 downregulation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17841-17847.	7.1	18
24	HIV portends a poor prognosis in myelodysplastic syndromes. Leukemia and Lymphoma, 2019, 60, 3529-3535.	1.3	15
25	Misidentification of MLL3 and other mutations in cancer due to highly homologous genomic regions. Leukemia and Lymphoma, 2019, 60, 3132-3137.	1.3	5
26	Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Seminars in Hematology, 2019, 56, 262-278.	3.4	25
27	Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clinical Cancer Research, 2019, 25, 6976-6985.	7.0	55
28	Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy?. Clinical Cancer Research, 2019, 25, 4868-4870.	7.0	6
29	U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nature Cell Biology, 2019, 21, 640-650.	10.3	165
30	Transcriptional regulators CITED2 and PU.1 cooperate in maintaining hematopoietic stem cells. Experimental Hematology, 2019, 73, 38-49.e7.	0.4	4
31	PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma. Clinical Cancer Research, 2019, 25, 3589-3601.	7.0	16
32	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discovery, 2019, 9, 778-795.	9.4	41
33	Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Advances, 2019, 3, 3962-3967.	5.2	12
34	Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nature Medicine, 2019, 25, 103-110.	30.7	169
35	Ascorbic acidâ€“induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma. Journal of Clinical Investigation, 2019, 129, 1612-1625.	8.2	64
36	Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. ELife, 2019, 8, .	6.0	103

#	Article	IF	Citations
37	A novel thrombopoietin mimetic RWJ-800088 increases megakaryopoiesis without causing malignant proliferation in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2019, 37, e18527-e18527.	1.6	0
38	Dynamic Regulation of Long-Chain Fatty Acid Oxidation by a Noncanonical Interaction between the MCL-1 BH3 Helix and VLCAD. Molecular Cell, 2018, 69, 729-743.e7.	9.7	45
39	Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Science Translational Medicine, 2018, 10, .	12.4	187
40	LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPÎ±-dependent enhancers in AML. Blood, 2018, 131, 1730-1742.	1.4	92
41	Metabolic strugGLS after FLT3 inhibition in AML. Blood, 2018, 131, 1631-1632.	1.4	1
42	STAT3 inhibition as a therapeutic strategy for leukemia. Leukemia and Lymphoma, 2018, 59, 2068-2074.	1.3	13
43	Inhibition of HIF1Î± Signaling: A Grand Slam for MDS Therapy?. Cancer Discovery, 2018, 8, 1355-1357.	9.4	2
44	Thrombopoietin receptorâ€“independent stimulation of hematopoietic stem cells by eltrombopag. Science Translational Medicine, 2018, 10, .	12.4	48
45	Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. Journal of Clinical Investigation, 2018, 128, 5479-5488.	8.2	68
46	IL1RAP potentiates multiple oncogenic signaling pathways in AML. Journal of Experimental Medicine, 2018, 215, 1709-1727.	8.5	61
47	A myeloid tumor suppressor role for NOL3. Journal of Experimental Medicine, 2017, 214, 753-771.	8.5	8
48	Stem and progenitor cell alterations in myelodysplastic syndromes. Blood, 2017, 129, 1586-1594.	1.4	93
49	ETO2-GLIS2: A Chimeric Transcription Factor Drives Leukemogenesis through a Neomorphic Transcription Network. Cancer Cell, 2017, 31, 307-308.	16.8	0
50	Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. Cancer Cell, 2017, 32, 490-505.e10.	16.8	128
51	ZNF143 protein is an important regulator of the myeloid transcription factor C/EBPÎ±. Journal of Biological Chemistry, 2017, 292, 18924-18936.	3.4	20
52	Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/Î²-Catenin Activation. Cancer Research, 2017, 77, 4846-4857.	0.9	61
53	Pharmacological inhibition of the transcription factor PU.1 in leukemia. Journal of Clinical Investigation, 2017, 127, 4297-4313.	8.2	89
54	Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways. Genome Research, 2017, 27, 1830-1842.	5.5	51

#	Article	IF	Citations
55	Efficacy of ALK5 inhibition in myelofibrosis. JCI Insight, 2017, 2, e90932.	5.0	37
56	Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.. Journal of Clinical Oncology, 2017, 35, 2505-2505.	1.6	71
57	DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders. Frontiers in Oncology, 2016, 6, 187.	2.8	38
58	Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy. Cell Stem Cell, 2016, 19, 6-8.	11.1	4
59	Molecular Mechanism of Mutant CALRâ€“Mediated Transformation. Cancer Discovery, 2016, 6, 344-346.	9.4	7
60	Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nature Cell Biology, 2016, 18, 607-618.	10.3	519
61	Ectopic DNMT3B expression delays leukemogenesis. Blood, 2016, 127, 1525-1526.	1.4	3
62	Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancer Research, 2016, 76, 4841-4849.	0.9	32
63	Targeting MDS and AML Stem Cells with AZD-9150 Mediated Inhibition of STAT3. Blood, 2016, 128, 4314-4314.	1.4	2
64	HIV Is Associated with a High Rate of Unexplained Multilineage Cytopenias and Portends a Poor Prognosis in Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood, 2016, 128, 4345-4345.	1.4	4
65	Analysis of overall survival in a large multiethnic cohort reveals absolute neutrophil count of 1,100 as a novel prognostic cutoff in African Americans. Oncotarget, 2016, 7, 67948-67955.	1.8	3
66	Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS-Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109. Blood, 2016, 128, 2749-2749.	1.4	0
67	Hispanic Ethnicity Is Associated with Younger Age at Presentation and Worse Survival in AML. Blood, 2016, 128, 3600-3600.	1.4	0
68	PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood, 2015, 126, 1118-1127.	1.4	49
69	IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood, 2015, 125, 3144-3152.	1.4	149
70	A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia. Nature Medicine, 2015, 21, 113-114.	30.7	3
71	Functionally Relevant RNA Helicase Mutations in Familial and Sporadic Myeloid Malignancies. Cancer Cell, 2015, 27, 609-611.	16.8	8
72	Mutational Cooperativity Linked to Combinatorial Epigenetic Gain of Function in Acute Myeloid Leukemia. Cancer Cell, 2015, 27, 502-515.	16.8	191

#	Article	IF	Citations
73	New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nature Chemical Biology, 2015, 11, 878-886.	8.0	151
74	Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia. Nature Medicine, 2015, 21, 1172-1181.	30.7	112
75	Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6359-68.	7.1	45
76	New Allosteric Inhibitors of Mutant IDH1 in Acute Myeloid Leukemia. Blood, 2015, 126, 787-787.	1.4	1
77	CITED2 Cooperates with Low PU.1 and DNMT3A to Maintain Self-Renewal in Hematopoietic Stem Cells. Blood, 2015, 126, 309-309.	1.4	0
78	Interleukin-1 Drives Precocious Myeloid Differentiation of Hematopoietic Stem Cells at the Expense of Self-Renewal. Blood, 2015, 126, 778-778.	1.4	0
79	Minimal Reduction of PU.1 Is Sufficient to Induce a Preleukemic State and Promote Development of Acute Myeloid Leukemia. Blood, 2015, 126, 305-305.	1.4	1
80	Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia. Molecular Cancer Therapeutics, 2014, 13, 1979-1990.	4.1	49
81	CDK6, a new target in MLL-driven leukemia. Blood, 2014, 124, 5-6.	1.4	8
82	HSC commitmentâ€“associated epigenetic signature is prognostic in acute myeloid leukemia. Journal of Clinical Investigation, 2014, 124, 1158-1167.	8.2	38
83	Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine. Blood, 2014, 124, 3602-3602.	1.4	6
84	Myelodysplastic Syndrome Marrow Stroma Shows Widespread Aberrant Hypermethylation That Is Abrogated By Treatment with Dnmt Inhibitors. Blood, 2014, 124, 4379-4379.	1.4	2
85	Exome Sequencing of Familial MDS Reveals Novel Mutations and High Rates of False Positive Mutations in MLL3 Due to Pseudogene Effects. Blood, 2014, 124, 4591-4591.	1.4	3
86	Efficacy of Dual Inhibition of p38 Mitogen Activated Protein Kinase (MAPK) and Tie-2 Kinase in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 2014, 124, 4628-4628.	1.4	0
87	PAK1 Is a Therapeutic Target in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2014, 124, 4614-4614.	1.4	0
88	Concise Review: Preleukemic Stem Cells: Molecular Biology and Clinical Implications of the Precursors to Leukemia Stem Cells. Stem Cells Translational Medicine, 2013, 2, 143-150.	3.3	58
89	Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. Nature Immunology, 2013, 14, 437-445.	14.5	92
90	Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1667-1675.	3.3	10

#	Article	IF	Citations
91	H2.0-Like Homeobox (HLX) Causes Pre-Leukemic Myeloid Expansion and Initiates AML In Cooperation With FLT3-ITD. Blood, 2013, 122, 4201-4201.	1.4	0
92	A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. Journal of Experimental Medicine, 2012, 209, 35-50.	8.5	67
93	Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood, 2012, 120, 2076-2086.	1.4	181
94	Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood, 2012, 120, 1290-1298.	1.4	165
95	Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood, 2012, 120, 386-394.	1.4	146
96	H2.0-like Homeobox Regulates Early Hematopoiesis and Promotes Acute Myeloid Leukemia. Cancer Cell, 2012, 22, 194-208.	16.8	39
97	Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML. Blood, 2012, 120, 1875-1875.	1.4	0
98	H2.0-Like Homeobox (HLX) Induces Unlimited Clonogenicity, Blocks Differentiation, and Cooperates with FLT3-ITD in the Induction of Acute Myeloid Leukemia. Blood, 2012, 120, 651-651.	1.4	0
99	Identification of a Novel Protein-Coding Gene (TIHL) and Its Functional Relevance in Myeloid Cells.. Blood, 2012, 120, 2333-2333.	1.4	0
100	PU.1 and p53 Double Mutant Mice Develop Aggressive AML with Dysplastic Features. Blood, 2012, 120, 769-769.	1.4	0
101	Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation.. Blood, 2012, 120, 2776-2776.	1.4	1
102	Aberrant Epigenetic and Genetic Marks Are Seen in Myelodysplastic Leukocytes and Reveal Dock4 as a Candidate Pathogenic Gene on Chromosome 7q. Journal of Biological Chemistry, 2011, 286, 25211-25223.	3.4	41
103	Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies. Best Practice and Research in Clinical Haematology, 2010, 23, 391-401.	1.7	36
104	Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome. International Journal of Hematology, 2009, 89, 173-187.	1.6	25
105	Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood, 2009, 114, 3899-3908.	1.4	119
106	Dysregulation of TGF-Beta Stimulated Smad Signaling Is Seen in Myelodysplasia and Points to the Potential Therapeutic Efficacy of TGF-Beta Receptor I Kinase Inhibition in Low Grade Disease.. Blood, 2009, 114, 737-737.	1.4	0
107	Neuropeptides Orexin A and B Are Funktionally Aktive in CD34+ Hematopoietic Stem and Progenitor Cells.. Blood, 2009, 114, 4593-4593.	1.4	0
108	The Neuropeptides Orexin a and B Have An Impact on Functional Properties of Human CD34+ Stem and Progenitor Cells.. Blood, 2008, 112, 1393-1393.	1.4	1

#	Article	IF	Citations
109	A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. Journal of Clinical Investigation, 2007, 117, 2611-2620.	8.2	109
110	A Distal Single Nucleotide Polymorphism Disrupts Development-Dependent Long-Range Transcriptional Regulation of the PU.1 Gene through the Chromatin-Remodeling Protein SATB1 in Acute Myeloid Leukemia.. Blood, 2007, 110, 3175-3175.	1.4	0
111	Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nature Genetics, 2006, 38, 27-37.	21.4	200
112	Essential role of Jun family transcription factors in PU.1 knockdownâ€“induced leukemic stem cells. Nature Genetics, 2006, 38, 1269-1277.	21.4	167
113	Effect of transcription-factor concentrations on leukemic stem cells. Blood, 2005, 106, 1519-1524.	1.4	93
114	Role of Transcription Factors C/EBPa and PU.1 in Normal Hematopoiesis and Leukemia. International Journal of Hematology, 2005, 81, 368-377.	1.6	66